# Filana Therapeutics, Inc.: financial statements, quarterly

FLNA · Nasdaq · CIK 1069530 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/flna.md) · [Financials](/companies/flna/financials.md) · [Filings](/companies/flna/filings.md) · [Insiders](/companies/flna/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/flna/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [25.0](/filings/0001437749-24-025611.md) | [23.6](/filings/0001437749-24-033944.md) | [18.7 d](/filings/0001437749-26-007962.md) | [16.2](/filings/0001437749-25-015478.md) | [15.2](/filings/0001437749-25-026686.md) | [17.7](/filings/0001437749-25-034427.md) | [20.5 d](/filings/0001437749-26-007962.md) | [13.7](/filings/0001437749-26-015664.md) | [5.1](/filings/0001437749-25-026686.md) | [4.0](/filings/0001437749-25-034427.md) | [3.9 d](/filings/0001437749-26-007962.md) | [4.5](/filings/0001437749-26-015664.md) |
| Operating income | $m | [(28.8)](/filings/0001437749-24-025611.md) | [(27.9)](/filings/0001437749-24-033944.md) | [(22.8) d](/filings/0001437749-26-007962.md) | [(19.9)](/filings/0001437749-25-015478.md) | [(61.4)](/filings/0001437749-25-026686.md) | [(30.6)](/filings/0001437749-25-034427.md) | [(29.5) d](/filings/0001437749-26-007962.md) | [(24.6)](/filings/0001437749-26-015664.md) | [(45.4)](/filings/0001437749-25-026686.md) | [(11.9)](/filings/0001437749-25-034427.md) | [(13.6) d](/filings/0001437749-26-007962.md) | [(11.2)](/filings/0001437749-26-015664.md) |
| Income tax | $m | [0.0](/filings/0001437749-24-025611.md) | [0.0](/filings/0001437749-24-033944.md) | not reported | [0.0](/filings/0001437749-25-015478.md) | [0.0](/filings/0001437749-25-026686.md) | [0.0](/filings/0001437749-25-034427.md) | [0.0 d](/filings/0001437749-25-005919.md) | [0.0](/filings/0001437749-26-015664.md) | [0.0](/filings/0001437749-25-026686.md) | [0.0](/filings/0001437749-25-034427.md) | [0.0 d](/filings/0001437749-26-007962.md) | [0.0](/filings/0001437749-26-015664.md) |
| Net income | $m | [(26.4)](/filings/0001437749-24-033944.md) | [(25.7)](/filings/0001437749-24-033944.md) | [(20.9) d](/filings/0001437749-26-007962.md) | [25.0](/filings/0001437749-25-034427.md) | [6.2](/filings/0001437749-25-034427.md) | [(27.9)](/filings/0001437749-25-034427.md) | [(27.6) d](/filings/0001437749-26-007962.md) | [(23.4)](/filings/0001437749-26-015664.md) | [(44.2)](/filings/0001437749-25-034427.md) | [(10.8)](/filings/0001437749-25-034427.md) | [(12.5) d](/filings/0001437749-26-007962.md) | [(10.3)](/filings/0001437749-26-015664.md) |
| Diluted EPS | $ per share | [(0.63)](/filings/0001437749-24-025611.md) | [(0.61)](/filings/0001437749-24-033944.md) | not reported | [(0.43)](/filings/0001437749-25-015478.md) | [0.13](/filings/0001437749-25-026686.md) | [(0.58)](/filings/0001437749-25-034427.md) | not reported | [(0.48)](/filings/0001437749-25-015478.md) | [(0.92)](/filings/0001437749-25-026686.md) | [(0.22)](/filings/0001437749-25-034427.md) | not reported | not reported |
| Basic EPS | $ per share | [(0.63)](/filings/0001437749-24-025611.md) | [(0.61)](/filings/0001437749-24-033944.md) | not reported | [0.58](/filings/0001437749-25-015478.md) | [0.13](/filings/0001437749-25-026686.md) | [(0.58)](/filings/0001437749-25-034427.md) | not reported | [(0.48)](/filings/0001437749-26-015664.md) | [(0.92)](/filings/0001437749-25-026686.md) | [(0.22)](/filings/0001437749-25-034427.md) | not reported | [(0.21)](/filings/0001437749-26-015664.md) |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [168](/filings/0001069530-23-000039.md) | [142](/filings/0001437749-24-033944.md) | [121](/filings/0001437749-25-005919.md) | [124](/filings/0001437749-24-016040.md) | [207](/filings/0001437749-24-025611.md) | [149](/filings/0001437749-24-033944.md) | [129](/filings/0001437749-26-007962.md) | [117](/filings/0001437749-25-015478.md) | [112](/filings/0001437749-25-026686.md) | [106](/filings/0001437749-25-034427.md) | [95.5](/filings/0001437749-26-015664.md) | [86.6](/filings/0001437749-26-015664.md) |
| Current assets | $m | [175](/filings/0001069530-23-000039.md) | [150](/filings/0001437749-23-030502.md) | [130](/filings/0001437749-25-005919.md) | [134](/filings/0001437749-24-016040.md) | [222](/filings/0001437749-24-025611.md) | [203](/filings/0001437749-24-033944.md) | [137](/filings/0001437749-26-007962.md) | [120](/filings/0001437749-25-015478.md) | [115](/filings/0001437749-25-026686.md) | [109](/filings/0001437749-25-034427.md) | [97.7](/filings/0001437749-26-015664.md) | [88.0](/filings/0001437749-26-015664.md) |
| Total assets | $m | [197](/filings/0001069530-23-000039.md) | [173](/filings/0001437749-23-030502.md) | [152](/filings/0001437749-25-005919.md) | [156](/filings/0001437749-24-016040.md) | [244](/filings/0001437749-24-025611.md) | [224](/filings/0001437749-24-033944.md) | [158](/filings/0001437749-26-007962.md) | [141](/filings/0001437749-25-015478.md) | [135](/filings/0001437749-25-026686.md) | [130](/filings/0001437749-25-034427.md) | [118](/filings/0001437749-26-015664.md) | [108](/filings/0001437749-26-015664.md) |
| Current liabilities | $m | [17.9](/filings/0001069530-23-000039.md) | [17.4](/filings/0001437749-23-030502.md) | [14.2](/filings/0001437749-25-005919.md) | [77.1](/filings/0001437749-24-016040.md) | [54.6](/filings/0001437749-24-025611.md) | [57.0](/filings/0001437749-24-033944.md) | [11.8](/filings/0001437749-26-007962.md) | [13.2](/filings/0001437749-25-015478.md) | [47.3](/filings/0001437749-25-026686.md) | [48.0](/filings/0001437749-25-034427.md) | [43.8](/filings/0001437749-26-015664.md) | [40.1](/filings/0001437749-26-015664.md) |
| Total liabilities | $m | [17.9](/filings/0001069530-23-000039.md) | [17.4](/filings/0001437749-23-030502.md) | [14.2](/filings/0001437749-25-005919.md) | not reported | not reported | [57.1](/filings/0001437749-24-033944.md) | [11.8](/filings/0001437749-26-007962.md) | [13.3](/filings/0001437749-25-015478.md) | [47.4](/filings/0001437749-25-026686.md) | [48.2](/filings/0001437749-25-034427.md) | [44.0](/filings/0001437749-26-015664.md) | [40.2](/filings/0001437749-26-015664.md) |
| Shareholders' equity | $m | [179](/filings/0001437749-24-033944.md) | [155](/filings/0001437749-24-033944.md) | [137](/filings/0001437749-26-007962.md) | [78.6](/filings/0001437749-25-034427.md) | [189](/filings/0001437749-25-034427.md) | [167](/filings/0001437749-25-034427.md) | [146](/filings/0001437749-26-015664.md) | [128](/filings/0001437749-26-015664.md) | [88.0](/filings/0001437749-25-034427.md) | [81.6](/filings/0001437749-25-034427.md) | [74.4](/filings/0001437749-26-015664.md) | [68.1](/filings/0001437749-26-015664.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(19.9) d](/filings/0001437749-24-025611.md) | [(26.5) d](/filings/0001437749-24-033944.md) | [(22.3) d](/filings/0001437749-26-007962.md) | [(19.1)](/filings/0001437749-25-015478.md) | [(18.2) d](/filings/0001437749-25-026686.md) | [(18.3) d](/filings/0001437749-25-034427.md) | [(61.3) d](/filings/0001437749-26-007962.md) | [(11.3)](/filings/0001437749-26-015664.md) | [(4.9) d](/filings/0001437749-25-026686.md) | [(6.2) d](/filings/0001437749-25-034427.md) | [(9.7) d](/filings/0001437749-26-007962.md) | [(8.9)](/filings/0001437749-26-015664.md) |
| Capital expenditure | $m | [(0.0) d](/filings/0001437749-24-025611.md) | [0.0 d](/filings/0001437749-24-033944.md) | [0.0 d](/filings/0001437749-26-007962.md) | [0.0](/filings/0001437749-25-015478.md) | [0.0 d](/filings/0001437749-25-026686.md) | [0.0 d](/filings/0001437749-25-034427.md) | [0.1 d](/filings/0001437749-26-007962.md) | [0.0](/filings/0001437749-25-015478.md) | [0.0 d](/filings/0001437749-25-026686.md) | [0.1 d](/filings/0001437749-25-034427.md) | [0.5 d](/filings/0001437749-26-007962.md) | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2013 (2013-03-31) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [44.9](/filings/0001193125-13-170549.md) | [40.0](/filings/0001069530-23-000017.md) | [40.0](/filings/0001069530-23-000039.md) | [41.7](/filings/0001437749-24-016040.md) | [41.8](/filings/0001437749-24-025611.md) | [42.0](/filings/0001437749-24-033944.md) | [44.1](/filings/0001437749-25-015478.md) | [46.2](/filings/0001437749-25-026686.md) | [48.0](/filings/0001437749-25-034427.md) | [48.3](/filings/0001437749-25-015478.md) | [48.3](/filings/0001437749-25-026686.md) | [48.3](/filings/0001437749-25-034427.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 48,307,896 at 2026-05-04, from the cover of the [10-Q filed 2026-05-07](/filings/0001437749-26-015664.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.